Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn's Disease and Ulcerative Colitis.

Although the lower prevalence of CR in the low-probability group compared with the intermediate- and high-probability groups did not reach statistical significance, the differences in CSFR between CDST response groups were statistically significant ( p = 0.04; Figure 2 ).

also in 53,799 other papers